Evidence map›Paper›PMID 31443472›Full record

ArticleInternational journal of molecular sciences2019

Prediction of Potential Drug-Disease Associations through Deep Integration of Diversity and Projections of Various Drug Features.

Ping Xuan, Yingying Song, Tiangang Zhang, Lan Jia

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Subgraph Neural Networks Enhanced by Global Similarity for Drug Repositioning.Interdisciplinary sciences, computational life sciences · 2026
    Article
  2. Review
  3. Article
  4. Drug Repositioning Based on Deep Sparse Autoencoder and Drug-Disease Similarity.Interdisciplinary sciences, computational life sciences · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ping XuanSchool of Computer Science and Technology, Heilongjiang University, Harbin 150080, China.
Yingying SongSchool of Computer Science and Technology, Heilongjiang University, Harbin 150080, China.
Tiangang ZhangSchool of Mathematical Science, Heilongjiang University, Harbin 150080, China. zhang@hlju.edu.cn.
Lan JiaSchool of Computer Science and Technology, Heilongjiang University, Harbin 150080, China.

Funding

China Postdoctoral Science Foundation 2019M650069Foundation of Graduate Innovative Research YJSCX2019-070HLJUFundamental Research Foundation of Universities in Heilongjiang Province for Technology Innovation KJCX201805Fundamental Research Foundation of Universities in Heilongjiang Province for Youth Innovation Team RCYJTD201805Heilongjiang Postdoctoral Scientific Research Staring Foundation BHL-Q18104National Natural Science Foundation of China 61702296, 61302139Natural Science Foundation of Heilongjiang Province LH2019F049, LH2019A029
6 · The paper itself

Abstract

Identifying new indications for existing drugs may reduce costs and expedites drug development. Drug-related disease predictions typically combined heterogeneous drug-related and disease-related data to derive the associations between drugs and diseases, while recently developed approaches integrate multiple kinds of drug features, but fail to take the diversity implied by these features into account. We developed a method based on non-negative matrix factorization, DivePred, for predicting potential drug-disease associations. DivePred integrated disease similarity, drug-disease associations, and various drug features derived from drug chemical substructures, drug target protein domains, drug target annotations, and drug-related diseases. Diverse drug features reflect the characteristics of drugs from different perspectives, and utilizing the diversity of multiple kinds of features is critical for association prediction. The various drug features had higher dimensions and sparse characteristics, whereas DivePred projected high-dimensional drug features into the low-dimensional feature space to generate dense feature representations of drugs. Furthermore, DivePred's optimization term enhanced diversity and reduced redundancy of multiple kinds of drug features. The neighbor information was exploited to infer the likelihood of drug-disease associations. Experiments indicated that DivePred was superior to several state-of-the-art methods for prediction drug-disease association. During the validation process, DivePred identified more drug-disease associations in the top part of prediction result than other methods, benefitting further biological validation. Case studies of acetaminophen, ciprofloxacin, doxorubicin, hydrocortisone, and ampicillin demonstrated that DivePred has the ability to discover potential candidate disease indications for drugs.

Indexed as

Deep LearningDisease SusceptibilityPharmaceutical PreparationsAlgorithmsComputational BiologyDrug-Related Side Effects and Adverse ReactionsHumansReproducibility of ResultsROC CurvePharmaceutical Preparationsdiversity representationdrug–disease associationnon-negative matrix factorizationprojections of drug featuresspecific features of different drug views

Identifiers

PMID31443472
PMCPMC6747548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.